Senzer's Critical Care Division has a focus on the development of novel inhaled medicines for clinical trial use in COVID-19 infection
Within our Critical Care Division, we will harness our expertise in developing inhaled medicines for use within clinical trials to create targeted anti-viral treatments for Covid-19.
Work is already underway on formulating two specific medicines with known anti-viral properties to allow inhaled delivery via pressurised metered-dose inhalers directly to the respiratory tract.
We believe that inhaler delivery may offer potential advantages over oral intake because it is directly targeted to the respiratory tract, easy to administer, and has the potential to require much lower doses than oral administration of the same medicine. This has the potential to reduce the occurrence of unwanted side effects; and so positively affecting the safety profile of the products being tested in forthcoming clinical trials.